Abstract O144 – Table 1. Meta‐analysis of dual therapy trials

Endpoint	Dual therapy	Triple therapy	Difference (95% CI)
HIV RNA <50 copies/mL FDA Snapshot	686/822 (83.5%)	644/802 (80.3%)	+2% (‐2% to +4%)
Protocol‐defined virological failure	41/822 (5.0%)	36/802 (4.5%)	0% (‐2% to +2%)
Treatment‐emergent drug resistance	5/822 (0.6%)	5/802 (0.6%)	0% (‐1% to +1%)

Country of research: United Kingdom. Key population: People living with HIV.